SCHEMBL2209105

SCHEMBL2209105

O=C(NCCCc1cc(F)cc(OCC2CCCCC2)c1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 4/20 0.40
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
ACACB O00763 1/20 0.37
ACACA Q13085 1/20 0.37
PARP15 Q460N3 3/20 0.37
MTNR1A P48039 3/20 0.37
MTNR1B P49286 3/20 0.37
NQO2 P16083 2/20 0.37
KAT6A Q92794 2/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADAMTS4 O75173 1/20 0.35
ADAMTS5 Q9UNA0 1/20 0.35
PDK2 Q15119 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4569120 0.89 PARP10 (0.38) PARP10THRATHRBACACBACACA
SCHEMBL2208238 0.85 ACACB (0.49) PARP10ACACBACACAMTNR1AMTNR1B
SCHEMBL2208665 0.83 KMT2A (0.37) PARP10THRATHRBACACBACACA
SCHEMBL2204138 0.77 PARP10 (0.45) PARP10THRATHRBPARP15
SCHEMBL4568835 0.77 CHRNB2 (0.41) PARP10THRATHRBPARP15
SCHEMBL2208152 0.76 PARP10 (0.39) PARP10PARP15KAT6APDK2
SCHEMBL2208146 0.76 PARP10 (0.39) PARP10PARP15KAT6APDK2
SCHEMBL17735445 0.70 KAT6A (0.48) PARP10PARP15KAT6ASMN1; SMN2PDK2
SCHEMBL20682479 0.70 TLR4 (0.36) PARP10THRATHRBPARP15KAT6A
SCHEMBL25819727 0.70 PARP10 (0.41) PARP10THRATHRBPARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 US disclosed
US-11446261-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2022-09-20 US disclosed
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2021-03-18 US disclosed
US-10639286-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2020-05-05 US disclosed
US-20190183816-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2019-06-20 US disclosed
US-10188615-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2019-01-29 US disclosed
US-20180177746-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2018-06-28 US disclosed
EP-3210966-A1 ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Acucela, Inc. (US) 2017-08-30 EP disclosed
US-9737496-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2017-08-22 US disclosed
US-9079825-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2015-07-14 US disclosed
US-8993807-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2015-03-31 US disclosed
US-8981153-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2015-03-17 US disclosed
US-8829244-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2014-09-09 US disclosed
US-20130197096-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA, INC. (US) 2013-08-01 US disclosed
US-20120214852-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-08-23 US disclosed
US-20120129894-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-24 US disclosed
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-17 US disclosed
US-7982071-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2011-07-19 US disclosed
US-20090326074-A1 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029708-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER PARP10 1846/4885THRA 3146/4885THRB 2187/4885
US-20190183816-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20130197096-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-11446261-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20120214852-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20090326074-A1 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-10188615-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20180177746-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-20120129894-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885
US-10639286-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER PARP10 1814/4885THRA 3099/4885THRB 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.